Envoy Medical (COCH) Q3 2025 earnings summary

Executive summary

• Eliminated over $32 million in debt, significantly improving the balance sheet and stockholder equity.

• Expanded global patent portfolio with multiple new issuances in the U.S., Europe, and Australia.

• Advanced pivotal clinical trial for fully implanted cochlear implant, reaching key milestones and receiving FDA approval to expand to the final stage.

• Raised additional capital post-quarter through a registered direct offering of up to $16 million.

Financial highlights

• Net revenue for Q3 2025 was $42,000, down from $56,000 in Q3 2024.

• R&D expenses decreased by $57,000 to $2.7 million year-over-year, with lower product costs offset by higher personnel costs.

• General and administrative expenses increased by $752,000 to $2.44 million, mainly due to public company costs and offering-related expenses.

• Operating loss for Q3 2025 was $5.71 million, compared to $4.97 million in Q3 2024.

• Net loss attributable to common stockholders was $7.75 million for Q3 2025, or $(0.35) per share.

• Cash at quarter end was $3.56 million, with additional capital raised after quarter close.

Outlook and guidance

• Enrollment in the final stage of the pivotal clinical trial has restarted, with strong patient interest.

• Management intends to accelerate momentum through the end of 2025, focusing on clinical and commercial progress.